Ahn, KJ, Lee, HS, Bai, SK and Song, CW (2013) Enhancement of radiation effect using beta-lapachone and underlying mechanism. Radiation Oncology Journal 31, 57–65.
Beg, MS, Huang, X, Silvers, MA, Gerber, DE, Bolluyt, J, Sarode, V, Fattah, F, Deberardinis, RJ, Merritt, ME, Xie, XJ, Leff, R, Laheru, D and Boothman, DA (2017) Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Journal of Surgical Oncology 116, 83–88.
Biederbick, A, Kern, HF and Elsasser, HP (1995) Monodansylcadaverine (MDC) is a specific in vivo marker for autophagic vacuoles. European Journal of Cell Biology 66, 3–14.
de Castro, SL, Batista, DG, Batista, MM, Batista, W, Daliry, A, de Souza, EM, Menna-Barreto, RF, Oliveira, GM, Salomão, K, Silva, CF, Silva, PB and Soeiro, MN (2011) Experimental chemotherapy for Chagas disease: a morphological, biochemical, and proteomic overview of potential Trypanosoma cruzi targets of amidines derivatives and naphthoquinones. Molecular Biology International 2011, 306928.
Docampo, R, Lopes, JN, Cruz, FS and Souza, W (1977). Trypanosoma cruzi: ultrastructural and metabolic alterations of epimastigotes by beta-lapachone. Experimental Parasitology 42, 142–149.
Dos Anjos, DO, Sobral Alves, ES, Gonçalves, VT, Fontes, SS, Nogueira, ML, Suarez-Fontes, AM, Neves da Costa, JB, Rios-Santos, F and Vannier-Santos, MA (2016) Effects of a novel β-lapachone derivative on Trypanosoma cruzi: parasite death involving apoptosis, autophagy and necrosis. International Journal for Parasitology: Drugs and Drug Resistance 6, 207–219.
Fernandes, MC, Da Silva, EN, Pinto, AV, De Castro, SL and Menna-Barreto, RF (2012) A novel triazolic naphthofuranquinone induces autophagy in reservosomes and impairment of mitosis in Trypanosoma cruzi. Parasitology 139, 26–36.
Garavaglia, PA, Cannata, JJB, Ruiz, AM, Maugeri, D, Duran, R, Galleano, M and Garcia, GA (2010) Identification, cloning and characterization of an aldo-keto reductase from Trypanosoma cruzi with quinone oxidoreductase activity. Molecular and Biochemical Parasitology 173, 132–141.
Garavaglia, PA, Laverrière, M, Cannata, JJ and García, GA (2016) Putative role of the aldo-keto reductase from Trypanosoma cruzi (TcAKR) in benznidazole metabolism. Antimicrobial Agents and Chemotherapy 60, 2664–2670.
Gerber, D, Arriaga, Y, Beg, MS, Dowell, JE, Schiller, JH, Frankel, AE, Leff, R, Meek, C, Bolluyt, J, Fatunde, O, Martinez, RT, Vo, P, Fattah, F, Sarode, V, Zhou, Y, Xie, Y, McLeod, M, Schwartz, B and Boothman, DA (2014) Phase 1 correlative study of ARQ761, a β-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosis. European Journal of Cancer 50, 84–85.
Goijman, SG and Stoppani, AO (1985) Effects of beta-lapachone, a peroxide-generating quinone, on macromolecule synthesis and degradation in Trypanosoma cruzi. Archives of Biochemistry and Biophysics 240, 273–280.
González, L, García-Huertas, P, Triana-Chávez, O, García, GA, Murta, S and Mejía-Jaramillo, AM (2017) Aldo-keto reductase and alcohol dehydrogenase contribute to benznidazole natural resistance in Trypanosoma cruzi. Molecular Microbiology 106, 704–718.
Grosso, NL, Bua, J, Perrone, AE, González, MN, Bustos, PL, Postan, M and Fichera, LE (2010) Trypanosoma cruzi: biological characterization of an isolate from an endemic area and its susceptibility to conventional drugs. Experimental Parasitology 126, 239–244.
Jamison, JM, Gilloteaux, J, Taper, HS, Calderon, PB and Summers, JL (2002) Autoschizis: a novel cell death. Biochemical Pharmacology 63, 1773–1783.
Koyama, J (2006) Anti-infective quinone derivatives of recent patents. Recent Patents on Anti-Infective Drug Discovery 1, 113–125.
Kubata, BK, Kabututu, Z, Nozaki, T, Munday, CJ, Fukuzumi, S, Ohkubo, K, Lazarus, M, Maruyama, T, Martin, SK, Duszenko, M and Urade, Y (2002) A key role for old yellow enzyme in the metabolism of drugs by Trypanosoma cruzi. The Journal of Experimental Medicine 196, 1241–1251.
Lazarin-Bidóia, D, Desoti, VC, Ueda-Nakamura, T, Dias Filho, BP, Nakamura, CV and Silva, SO (2013) Further evidence of the trypanocidal action of eupomatenoid-5: confirmation of involvement of reactive oxygen species and mitochondria owing to a reduction in trypanothione reductase activity. Free Radical Biology and Medicine 60, 17–28.
Lopes, JN, Cruz, FS, Docampo, R, Vasconcellos, ME, Sampaio, MC, Pinto, AV and Gilbert, B (1978) In vitro and in vivo evaluation of the toxicity of 1,4-naphthoquinone and 1,2-naphthoquinone derivatives against Trypanosoma cruzi. Annals of Tropical Medicine and Parasitology 72, 523–531.
Matsunaga, T, Arakaki, M, Kamiya, T, Endo, S, El-Kabbani, O and Hara, A (2009) Involvement of an aldo-keto reductase (AKR1C3) in redox cycling of 9,10-phenanthrenequinone leading to apoptosis in human endothelial cells. Chemico-Biological Interactions 181, 52–60.
Menna-Barreto, RF, Salomão, K, Dantas, AP, Santa-Rita, RM, Soares, MJ, Barbosa, HS and de Castro, SL (2009) Different cell death pathways induced by drugs in Trypanosoma cruzi: an ultrastructural study. Micron 40, 157–168.
Molina Portela, MP, Fernandez Villamil, SH, Perissinotti, LJ and Stoppani, AO (1996) Redox cycling of o-naphthoquinones in trypanosomatids. Superoxide and hydrogen peroxide production. Biochemical Pharmacology 52, 1875–1882.
Ogindo, CO, Khraiwesh, MH, George, M Jr., Brandy, Y, Brandy, N, Gugssa, A, Ashraf, M, Abbas, M, Southerland, WM, Lee, CM, Bakare, O and Fang, Y (2016) Novel drug design for Chagas disease via targeting Trypanosoma cruzi tubulin: homology modeling and binding pocket prediction on Trypanosoma cruzi tubulin polymerization inhibition by naphthoquinone derivatives. Bioorganic & Medicinal Chemistry 24, 3849–3855.
Park, EJ, Min, KJ, Lee, TJ, Yoo, YH, Kim, YS and Kwon, TK (2014) β-Lapachone induces programmed necrosis through the RIP1-PARP-AIF-dependent pathway in human hepatocellular carcinoma SK-Hep1 cells. Cell Death & Disease 5, e1230.
Pieretti, S, Haanstra, JR, Mazet, M, Perozzo, R, Bergamini, C, Prati, F, Fato, R, Lenaz, G, Capranico, G, Brun, R, Bakker, BM, Michels, PA, Scapozza, L, Bolognesi, ML and Cavalli, A (2013) Naphthoquinone derivatives exert their antitrypanosomal activity via a multi-target mechanism. PLoS Neglected Tropical Diseases 7, 1e12.
Pink, JJ, Planchon, SM, Tagliarino, C, Varnes, ME, Siegel, D and Boothman, DA (2000) NAD(p)H:quinone oxidoreductase activity is the principal determinant of betalapachone cytotoxicity. The Journal of Biological Chemistry 275, 5416–5424.
Ramos, EI, Garza, KM, Krauth-Siegel, RL, Bader, J, Martinez, LE and Maldonado, RA (2009) 2,3-Diphenyl-1,4-naphthoquinone: a potential chemotherapeutic agent against Trypanosoma cruzi. The Journal of Parasitology 95, 461–466.
Salas, C, Tapia, RA, Ciudad, K, Armstrong, V, Orellana, M, Kemmerling, U, Ferreira, J, Maya, JD and Morello, A (2008) Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms. Bioorganic & Medicinal Chemistry 16, 668–674.
Salas, CO, Faúndez, M, Morello, A, Maya, JD and Tapia, RA (2011) Natural and synthetic naphthoquinones active against Trypanosoma cruzi: an initial step towards new drugs for Chagas disease. Current Medicinal Chemistry 18, 144–161.
Salmon-Chemin, L, Buisine, E, Yardley, V, Kohler, S, Debreu, MA, Landry, V, Sergheraert, C, Croft, SL, Krauth-Siegel, RL and Davioud-Charvet, E (2001) 2- and 3-substituted 1,4-naphthoquinone derivatives as subversive substrates of trypanothione reductase and lipoamide dehydrogenase from Trypanosoma cruzi: synthesis and correlation between redox cycling activities and in vitro cytotoxicity. Journal of Medicinal Chemistry 44, 548–565.
Salomao, K, De Santana, NA, Molina, MT, De Castro, SL and Menna-Barreto, RF (2013) Trypanosoma cruzi mitochondrial swelling and membrane potential collapse as primary evidence of the mode of action of naphthoquinone analogues. BMC Microbiology 3, 1e13.
Sengupta, S, Chowdhury, S, Bosedasgupta, S, Wright, CW and Majumder, HK (2011) Cryptolepine-induced cell death of Leishmania donovani promastigotes is augmented by inhibition of autophagy. Molecular Biology International 2011, 187850.
Silva, MT (2010) Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Letters 584, 4491–4499.
Silva, JS, Ferrioli-Filho, F, Kanesiro, MM, Ferreira, VF, Santos, SC, Pinto, CN, Fonseca, JL, Mizrahy, HE, Gilbert, B, Pinto, MC, Ribeiro, FW and Pinto, AV (1992) Evaluation of some organic compounds on bloodstream forms of Trypanosoma cruzi. Memórias do Instituto Oswaldo Cruz 87, 345–351.
Smirlis, D, Duszenko, M, Ruiz, AJ, Scoulica, E, Bastien, P, Fasel, N and Soteriadou, K (2010) Targeting essential pathways in trypanosomatids gives insights into protozoan mechanisms of cell death. Parasites & Vectors 3, 107–122.
Sosa-Estani, S, Viotti, R and Segura, EL (2009) Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina. Memórias do Instituto Oswaldo Cruz 104, 167–180.
Taguchi, K, Fujii, S, Yamano, S, Cho, AK, Kamisuki, S, Nakai, Y, Sugawara, F, Froines, JR and Kumagai, Y (2007) An approach to evaluate two-electron reduction of 9,10-phenanthraquinone and redox activity of the hydroquinone associated with oxidative stress. Free Radical Biology & Medicine 43, 789–799.
Taylor, MC and Kelly, JM (2006) pTcINDEX: a stable tetracycline-regulated expression vector for Trypanosoma cruzi. BioMed Central Biotechnology 6, 32–50.
Veiga-Santos, P, Barrias, ES, Santos, JF, de Barros Moreira, TL, de Carvalho, TM, Urbina, JA and de Souza, W (2012) Effects of amiodarone and posaconazole on the growth and ultrastructure of Trypanosoma cruzi. International Journal of Antimicrobial Agents 40, 61–71.
Zingales, B, Pereira, ME, Oliveira, RP, Almeida, KA, Umezawa, ES, Souto, RP, Vargas, N, Cano, MI, da Silveira, JF, Nehme, NS, Morel, CM, Brener, Z and Macedo, A (1997) Trypanosoma cruzi genome project: biological characteristics and molecular typing of clone CL Brener. Acta Tropica 68, 159–173.
Zong, WX and Thompson, CB (2006) Necrotic death as a cell fate. Genes and Development 20, 1–15.